ARTICLE | Clinical News
561679: Phase II started
August 9, 2010 7:00 AM UTC
Neurocrine disclosed in its earnings that partner GlaxoSmithKline began a double-blind, placebo-controlled Phase II trial to evaluate oral 561679 in about 150 patients. The companies are developing CR...